Inventor · disambiguated record
Melissa Marie Vasbinder
Also filed as: VASBINDER MELISSA · VASBINDER MELISSA MARIE
21 granted patents·17 pending applications·61 citations·filing 2006–2024
94Inventor score
Files withRIBON THERAPEUTICS INC25ASTRAZENECA AB6BOEHRINGER INGELHEIM INT3DIZAL JIANGSU PHARMACEUTICAL CO LTD3ASTRAZENECA1
Top patents by PatentIndex Score
38 records- 0197US11014913B2Pyridazinones as PARP7 inhibitorsRIBON THERAPEUTICS INC·Filed 2020·Granted May 25, 2021·6 cites·13 claims
- 0297US10550105B2Pyridazinones as PARP7 inhibitorsRIBON THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·13 cites·8 claims
- 0395US11566020B1Pyridazinones as PARP7 inhibitorsRIBON THERAPEUTICS INC·Filed 2021·Granted Jan 31, 2023·3 cites·26 claims
- 0494US10870641B2Pyridazinones as PARP7 inhibitorsRIBON THERAPEUTICS INC·Filed 2019·Granted Dec 22, 2020·6 cites·30 claims
- 0593US11535621B2Heterobicyclic amides as inhibitors of CD38RIBON THERAPEUTICS INC·Filed 2020·Granted Dec 27, 2022·3 cites·4 claims
- 0692US11987584B2Heterobicyclic amides as inhibitors of CD38RIBON THERAPEUTICS INC·Filed 2022·Granted May 21, 2024·1 cites·22 claims
- 0792US10562891B2Quinazolinones as PARP14 inhibitorsRIBON THERAPEUTICS INC·Filed 2018·Granted Feb 18, 2020·5 cites·4 claims
- 0889US11952377B2Quinolines and azaquinolines as inhibitors of CD38BOEHRINGER INGELHEIM INT·Filed 2022·Granted Apr 9, 2024·1 cites·9 claims
- 0989US11293927B2Screening methods for PARP modulatorsRIBON THERAPEUTICS INC·Filed 2019·Granted Apr 5, 2022·3 cites·14 claims
- 1088US9714236B2Compounds and methods for inhibiting JAKASTRAZENECA AB·Filed 2016·Granted Jul 25, 2017·6 cites·5 claims
- 1186US11247983B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Feb 15, 2022·2 cites·19 claims
- 1286US10167276B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2017·Granted Jan 1, 2019·5 cites·5 claims
- 1386US2025034120A1Pyridazinones as parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1485US11691969B2Pyridazinones as PARP7 inhibtorsRIBON THERAPEUTICS INC·Filed 2020·Granted Jul 4, 2023·1 cites·75 claims
- 1584US10654835B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2018·Granted May 19, 2020·3 cites·22 claims
- 1683US12398146B2Heterobicyclic amides as inhibitors of CD38BOEHRINGER INGELHEIM INT·Filed 2024·Granted Aug 26, 2025·0 cites·53 claims
- 1782US12371421B2Solid forms of a PARP7 inhibitorRIBON THERAPEUTICS INC·Filed 2020·Granted Jul 29, 2025·1 cites·20 claims
- 1882US11008308B2Quinazolinones as PARP14 inhibitorsRIBON THERAPEUTICS INC·Filed 2020·Granted May 18, 2021·1 cites·2 claims
- 1982US2025020654A1Screening methods for parp modulatorsRIBON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2080US2023192664A1Pyridazinones as parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2176US2025074897A1Pyridazinones as parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2275US2025064803A1Dosage regimens for parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2374US9845331B2Chemical compoundsASTRAZENECA AB·Filed 2016·Granted Dec 19, 2017·1 cites·8 claims
- 2474US2024279224A1Quinolines and azaquinolines as inhibitors of cd38BOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 2573US2022340592A1Chemical compoundsASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 2673US2024325391A1Dosage regimens for parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2773US2022206008A1Screening methods for parp modulatorsRIBON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2872US2024034728A1Pyridazinones as parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2968US11958837B2Quinazolinones as PARP14 inhibitorsRIBON THERAPEUTICS INC·Filed 2021·Granted Apr 16, 2024·0 cites·46 claims
- 3068US11352369B2Pyridine and pyrimidine derivativesASTRAZENECA AB·Filed 2020·Granted Jun 7, 2022·0 cites·19 claims
- 3167US2022265654A1Dosage regimens for parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3261US10717746B2Chemical compoundsASTRAZENECA AB·Filed 2017·Granted Jul 21, 2020·0 cites·6 claims
- 3361US2024190844A1Pyridazinones as parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3461US2023303542A1Solid forms of a parp14 inhibitorRIBON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3559US2022265655A1Methods of treating inflammatory diseasesRIBON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3650US2022388985A1Targeted protein degradation of parp14 for use in therapyRIBON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3747US2010216791A1Pyridinylquinazolinamine derivatives and their use as b-raf inhibitorsASTRAZENECA·Filed 2007·Application pending·0 cites
- 3841US2009275570A1Substituted heterocycles and their use as chk1, pdk1 and pak inhibitorsASTRAZENECA AB·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Melissa Marie Vasbinder files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →